New Two-Drug combo aims to boost immune attack on lung cancer
Disease control
Recruiting now
This study is testing a personalized treatment approach for people with locally advanced non-small cell lung cancer (NSCLC). It combines a new two-drug immunotherapy regimen (cemiplimab and fianlimab) with targeted radiation therapy. The goal is to see if this combination can bet…
Phase: PHASE2 • Sponsor: Nitin Ohri • Aim: Disease control
Last updated Apr 02, 2026 05:41 UTC